Abstract The antimicrobial drug candidate 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene silver(I) acetate (SBC3) was evaluated for its ability to function in vivo using larvae of Galleria mellonella. A SBC3 concentration of 25 lg/ml inhibited the growth of Staphylococcus aureus by 71.2 % and Candida albicans by 86.2 % in vitro. Larvae inoculated with 20 ll of SBC3 solution showed no ill effects up to a concentration of 250 lg/ml but administration of 500 lg/ml resulted in a 40 % reduction in larval survival and administration of a dose of 1,000 lg/ml resulted in total larval death at 24 h. Larvae inoculated with S. aureus or C. albicans and subsequently administered SBC3 showed increased survival. Administration of SBC3 to larvae did not boost the insect immune response as indicated by lack of an increase in the density of circulating haemocytes (immune cells). The abundance of a number of proteins involved in the insect immune response was reduced in larvae that received 20 ll SBC3 solution of 100 lg/ml. This is the first demonstration of the in vivo activity of SBC3 against S. aureus and C. albicans and demonstrates that SBC3 does not stimulate a non-specific immune response in larvae.
Introduction
Extensive use and misuse of the available antibiotic arsenal and the shortage of new drugs reaching the market have made antimicrobial resistance a major threat to healthcare worldwide (Maple et al. 1989) . The continuous development of novel resistancedisrupting antimicrobial drugs should therefore be a prime activity of industry and academia (Rex 2014) . There is significant unexplored space for antimicrobial silver-based drugs (Mijnendonckx et al. 2013; Oehninger et al. 2013) and it has been suggested that carbene-silver acetates derived from methylated caffeine may have the stability and antibiotic activity to become drug candidates (Kascatan-Nebioglu et al. 2006; Hindi et al. 2008) . This idea led to the development of more lipophilic benzyl-substituted imidazole-and benzimidazole-derived carbene-silver complexes showing activity against Gram-positive and Gram-negative bacteria (Hackenberg and Tacke 2014; . So far, the most promising derivative is 1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene silver(I) acetate (SBC3) (Fig. 1) . SBC3 shows MIC values ranging from 20 to 3.13 lg/ml against Methicillin-sensitive and -resistant Staphylococcus aureus as well as Salmonella, Escherichia coli and Pseudomonas aeruginosa (Sharkey et al. 2012) .
Evaluating the in vivo efficacy and stability of novel antimicrobial compounds is possible using insects. The insect immune system shows many similarities to the innate immune system of mammals (Kavanagh and Reeves 2004; Browne et al. 2013 ) and, as a consequence, insects have been used as models to measure the virulence of microbial pathogens (Fuchs and Mylonakis 2006) and to evaluate the potency of antimicrobial drugs (Hamamoto et al. 2004; Rowan et al. 2009 ) and give results consistent with those that can be obtained using mammals (Jander et al. 2000; Brennan et al. 2002) . A number of insect species can be employed for evaluating the in vivo activity of novel antimicrobial drugs (Kavanagh and Fallon 2010) and larvae of the Greater Wax Moth, Galleria mellonella are now widely used in this capacity (Kelly and Kavanagh 2011; Rowan et al. 2009; Desbois and Coote 2012) . This paper describes the antimicrobial effects of SBC3 against the bacterium S. aureus and the yeast Candida albicans in vitro and demonstrates the in vivo activity and toxicity of SBC3 against these two pathogens in G. mellonella larvae.
Materials and methods

Synthesis of SBC3
SBC3 (1,3-dibenzyl-4,5-diphenyl-imidazol-2-ylidene silver(I) acetate) was synthesised as published ) and dissolved in a minimal amount of DMSO (dimethylsulfoxide) before being diluted with water-based media as described.
Inoculation of G. mellonella larvae Sixth instar larvae of G. mellonella (Lepidoptera: Pyralidae, the Greater Wax Moth) (Mealworm Company, Sheffield, England) were stored in the dark at 15°C (Cotter et al. 2000; Hornsey and Wareham 2011) . Larvae of the same age and weighing 0.3 g were inoculated with 20 ll of PBS containing 1 9 10 6 C. albicans cells or 4 9 10 7 S. aureus cells through the last pro-leg using a Myjector U100 insulin syringe (Terumo Europe, Leuven, Belgium).
Microbial cell culture
Staphylococcus aureus was cultured to the stationary phase (OD 600nm = 2) overnight in nutrient broth at 37°C and 200 rpm. C. albicans was cultured to the stationary phase (approx. 1 9 10 8 /ml) overnight in YEPD broth (2 % (w/v) glucose, 2 % (w/v) bacteriological peptone, 1 % (w/v) yeast extract) at 30°C and 200 rpm.
Effect of SBC3 on growth of S. aureus and C. albicans
To each well of a 96-well plate (Sarsdedt), 100 ll of fresh nutrient broth medium (for S. aureus growth) or minimal medium (2 % (w/v) glucose, 0.17 % (w/v) yeast nitrogen base and 0.5 % (w/v) ammonium sulphate) (for C. albicans growth) were added. A serial dilution of SBC3 was perfomed on the plate to give a concentration range of 0.39-100 lg/ml. Cell suspensions (100 ll) of S. aureus (4 9 10 7 cells/ml) or C. albicans (1 9 10 6 cells/ml) were added to each well and the plates were incubated at 37 or 30°C, respectively, for 24 h. The OD 570nm of the cultures was determined using a microplate reader (Bio-Tek, Synergy HT) and all growth was expressed as a percentage of that in the control. All susceptibility assays were performed on three separate occasions.
In vivo toxicity assay Larvae were injected with 20 ll of SBC3 solution (10, 100, 250, 500 or 1,000 lg/ml) or 5 % (v/v) DMSO through the last left pro-leg as described. Larvae were incubated at 30°C for 24 h prior to quantifying survival.
Effect of SBC3 on survival of larvae infected with S. aureus or C. albicans Larvae were injected with 20 ll of SBC3 solution (10, 100 or 250 lg/ml) 4 h post-inoculation with S. aureus or C. albicans. The control consisted of larvae inoculated with the C. albicans or S. aureus. Larvae were incubated at 30°C and survival was assessed at 24, 48 and 72 h.
Determination of larval haemocyte density
The density of circulating haemocytes in larvae was assessed as described previously (Rowan et al. 2009 ). Experiments were performed on three independent occasions and the mean ± SE were determined.
D SDS-PAGE analysis of protein expression in larvae administered SBC3
Haemolymph (100 ll) was collected from larvae inoculated with 20 ll SBC3 (100 lg/ml) or 5 % (v/ v) DMSO following incubation at 30°C for 24 h. Protein concentration was determined by Bradford assay and protein was diluted to 200 lg per sample. Isoelectric focusing of protein samples on a pH 4-7 strip and 2D electrophoresis was performed as described previously (Bergin et al. 2006) . Each 2D gel was scanned on a Hewlett Packard scanjet 5100c scanner and the images were analyzed using Progenesis SameSpot Software. The Progenesis software enabled the analysis of protein expression changes between gel replicates with significance determined using ANOVA. A table of protein spots was built and every protein was linked to the matching proteins between the gels creating a list of proteins that can be cross referenced as a final check to ensure correct alignment.
LC/MS analysis of peptides
In-gel digestion was performed on 2-Dimensional gel spots of interest from a reference gel. The gel pieces were excised, trypsin digested (Shevchenko et al. 2006 ) and fragmented protein samples were eluted through the LC/MS (Aglient 6340 Ion Trap) which determines the relative charge to mass ratio from detected ionized particles. The data were analysed using the mascot search engine to identify the protein (\http://www.matrixscience.com) or via (*) Spectrum Mill MS Proteomics. MASCOT scores above 67 are deemed to have a significant match (p \ 0.05). The mass error tolerance was 1 Da allowing for a maximum of no more than two missed cleavages. Verification of protein sequences was confirmed by blasting the protein sequence on the Uniprot (www.uniprot. org) and NCBI (www.ncbi.nlm.nih.gov) websites. Progenesis was used to determine the protein fold changes between 2-Dimensional gels.
Statistical analysis
All experiments were performed on three independent occasions and results are expressed as the mean ± SE. Changes in larval survival were analysed with the log rank (Mantel-Cox) method using GraphPad Prism version 5.00. Analysis of changes in haemocyte density, in vitro toxicity and protein expression were performed by One-way ANOVA using GraphPad Prism version 5.00 for Windows 8, GraphPad Software, San Diego, California USA, (www.graphpad. com).
Results
Determination of in vitro efficacy of SBC3 against S. aureus and C. albicans
The effect of SBC3 on the growth of S. aureus and C. albicans was measured as described. In the case of S. aureus a concentration of 25 lg/ml resulted in 71.2 ± 1.28 % (p \ 0.001) inhibition of growth (Fig. 2) while the same concentration resulted in 86.2 ± 1.42 % (p \ 0.001) inhibition in the growth of C. albicans (Fig. 2) . Both microbes appear susceptible to SBC3 but there appears to be greater inhibition of the growth of C. albicans than S. aureus at the higher concentrations ([25 lg/ml).
Determination of effect of SBC3 on larval viability
The effect of SBC3 on the viability of G. mellonella larvae was assessed as described. The results (Fig. 3 ) Biometals (2014) 27:745-752 747 indicate no toxic effect up to a concentration of 250 lg/ml however larvae inoculated with a dose of 500 lg/ml showed a 40.0 ± 11.54 % (p \ 0.01) reduction in viability after 24 h. Larvae inoculated with SBC3 (10, 100, 250 lg/ml) did not show signs of cuticular darkening (melanisation) which would be an indicator of acute toxicity.
Effect of SBC3 on survival of larvae infected with S. aureus or C. albicans
In order to ascertain the in vivo activity of SBC3, larvae were infected with each pathogen as described and subsequently administered 20 ll of SBC3 (10, 100 or 250 lg/ml) 4 h post infection. Those larvae infected with S. aureus showed 15 ± 5.0 % survival at 72 h however the larvae administered a dose of 10, 100 or 250 lg/ml SBC3 showed 46.7 ± 12.01 % (p \ 0.05), 36.7 ± 3.33 % and 40.0 ± 5.77 % survival, respectively, at the same time point (Fig. 4a ). Larvae inoculated with C. albicans alone showed 100 % mortality at 48 h. However those larvae inoculated with a dose of 10, 100 or 250 lg/ml SBC3 subsequent to infection showed 30 ± 5.77 % (p \ 0.01), 16.7 ± 6.66 % (p \ 0.05) and 13.3 ± 3.33 % (p \ 0.05) survival at the same time point, respectively (Fig. 4b) .
Assessment of the effect of SBC3 on the immune response G. mellonella larvae
The cellular immune response of insects is mediated by immune cells (haemocytes) which phagocytose and kill invading pathogens (Lavine and Strand 2002) and by the production of antimicrobial peptides (Boman and Hultmark 1987) . Previous work has demonstrated that introduction of selected agents (e.g. silver nitrate, caspofungin, b-glucan) into the haemocoel of G. mellonella larvae can prime the immune response and lead to an increase in the density of circulating haemocytes and in the expression of antimicrobial and immune related peptides (Rowan et al. 2009; Kelly and Kavanagh 2011; Mowlds et al. 2010) . In order to exclude the possibility that the observed in vivo antimicrobial activity of SBC3 was due to the increased density of immune cells in the larvae, the density of circulating haemocytes in larvae was assessed. The results indicate that there was no significant change in the haemocyte density in those larvae that received doses of 10 and 100 lg/ml SBC3 (Fig. 5) . Those larvae that received 20 ll doses of 500 or 1,000 lg/ml demonstrated a 76.7 ± 1.0 % or 55.9 ± 4.0 % reduction, respectively, in haemocyte density relative to the control. This may have arisen due to lysis of the haemocytes by the SBC3.
The humoral immune response of insects is mediated by a series of antimicrobial peptides and immune related peptides (Kavanagh and Reeves 2004) . The proteomic profile of larvae that had received SBC3 was analysed in order to determine whether exposure to the compound increased this element of the larval immune response (Fig. 6) . The results indicate that the abundance of a number of proteins is reduced in larvae that received SBC3 (Table 1 ). Proteins such as larval Fig. 2 In vitro toxicity of SBC3 to S. aureus and C. albicans Fig. 3 Larval survival 24 h after administration with 20 ll of control solution (5 % DMSO) or SBC3 (10, 100, 250, 500, 1,000 lg/ml) haemolymph protein, 27 kDa haemolymph protein and apolipophorin-3 were decreased in intensity. The abundance of arylphorin was increased by 2-fold.
Discussion
Due to the many similarities between the immune system of insects and the innate immune system of mammals, insects have become popular choices for measuring the virulence of microbial pathogens and give results comparable to those that can be obtained using mammals (Brennan et al. 2002; Jander et al. 2000) . Insects have the benefit of being inexpensive to purchase and house, and can give results in 24-48 h. Insect can also be used to evaluate the in vivo activity of antimicrobial drugs (Hamamoto et al. 2004; ) but caution must be exercised in their use as the introduction of foreign material into the insect haemoceol can provoke a non-specific immune response (Mowlds et al. 2010; Kelly and Kavanagh 2011) .
The antimicrobial activity of silver is well established (Percival et al. 2005 ) and silver has been incorporated into many medical products (e.g. catheters, plasters) where it can limit the growth of bacteria and the development of biofilms (Adams et al. 1999) . While the mode of action of silver is not fully elucidated it has been shown to inactivate NADH and succinate dehydrogenase and so interfere with electron transfer in respiration (Park et al. 2009 ). Exposure to silver may also lead to the generation of reactive oxygen species (ROS) which induces protein and DNA degradation (Park et al. 2009; Atiyeh et al. 2007; Castellano et al. 2007) . Previous work demonstrated the induction of an oxidative stress response in C. albicans when exposed to Ag(I) ions (Rowan et al. 2010) .
The experimental drug SBC3 was demonstrated to be of low toxicity to G. mellonella larvae and the results presented here indicated that larvae infected with C. albicans or S. aureus and subsequently administered SBC3 demonstrated increased survival. SBC3 does not provoke an enhanced immune response as indicated by the lack of an increase in the haemocyte density and the expression of antimicrobial and immune related peptides. A number of proteins were shown to decrease in abundance in larvae that received SBC3 and these included carboxylesterase (spot 3, Table 1 ) which has physiological functions in neurotransmitter degradation, hormone and pheromones specific metabolism, detoxification, defense and behavior (Vogt et al. 1985; Taylor and Radic 1994) , 27 kDa haemolymph protein (spot 2) which is secreted into the haemolymph as a signal molecule (Kelly and Kavanagh 2011 ) and apolipophorin-3 (spot 8) which functions in the innate immune response (Gupta et al. 2010) . Spot 6, hypothetical protein YQE_03765 partial, was increased in abundance in larvae that received SBC3 and functions as a death domain protein with roles in apoptosis, immune defense, and immune signalling (Lahm et al. 2003) . The abundance of arylphorin (spot 1), which is involved in storage of amino acids and in aiding the immune defence of insects (Beresford et al. 1997) , was increased in abundance by 2-fold. In contrast, administration of silver nitrate to G. mellonella larvae stimulated the immune response by increasing the density of circulating haemocytes (Rowan et al. 2009 ). One possibility for this difference in the response of G. mellonella larvae to silver in silver nitrate and in SBC3, is that silver nitrate releases ionic Ag ? and NO3-in biological media, whereas SBC3 is covalently bonded L-Ag-OAc (L = NHC) and no free Ag ? is formed. The lipid nature of SBC3 may not provoke an immune response as it may be better tolerated by the insect's immune system. As a consequence it can be concluded that the increased survival of larvae that received SBC3 is due to the anti-microbial properties of the compound and not to a non-specific immune response induced by the introduction of the compound. This is the first demonstration of the in vivo activity of SBC3 against S. aureus and C. albicans. Future studies will assess the mode of action of the compound in insect larvae and mice followed by survival as well as PK/PD studies in rodents. It is hoped that SBC3 may be developed into an intravenous antibiotic for use against pathogenic bacteria and fungi that show resistance to conventional antimicrobial drugs.
